Background: Rates of septicemia/sepsis mortality and hospitalization in the US have risen significantly during the recent years, and antibiotic use may contribute to those rates through various mechanisms.
Introduction
Rates of hospitalization with septicemia and sepsis, associated mortality and monetary costs have been rising rapidly during the past decades in the US [1] [2] [3] [4] .
Moreover, the US CDC estimate of 270,000 annual deaths in the US resulting from sepsis [5] is expected to increase significantly if longer-term (e.g. 90-day) mortality following hospitalization with septicemia/sepsis were accounted for [6] . While changes in diagnostic practices contributed to the growth in the volume of hospitalizations with septicemia/sepsis in the diagnosis [7, 8] , those changes cannot fully explain the rise in the rates of hospitalization with septicemia/sepsis, particularly prior to 2010 [9] . Indeed, trends in the rates of US hospitalizations with any diagnosis of sepsis between 2003-2009 closely resemble the trends in the rates of hospitalizations that involved infection and the use of mechanical ventilation (Figure 1 in [9] ). Use of antibiotics and antibiotic resistance may also contribute to the rates of hospitalization with septicemia and the associated mortality [10] [11] [12] [13] . Antibiotic resistance and use can facilitate the progression to a severe disease state when infections not cleared by antibiotics prescribed during outpatient and/or the inpatient treatment may eventually devolve into sepsis, e.g. [14, 15] . Antibiotic use may also contribute to prevalence of infections resistant to other antibiotics that may lead to severe outcomes. For example, fluoroquinolone use was found to be associated with methicillin-resistant S. aureus (MRSA) infections [16, 17] , while amoxicillin use was found to be associated with trimethoprim resistance in Enterobacteriaceae [18] , with trimethoprim-resistant urinary tract infections (UTIs) leading to bacteremia outcomes [15] .
Our previous work had suggested associations between the use of penicillins and fluoroquinolones, antibiotic resistance, and rates of septicemia hospitalization in US adults [10, 11, 19] . In this paper we study the relation between the rates of outpatient prescribing for different antibiotic classes and the rates of mortality with septicemia (ICD-10 codes A40-41 present as either the underlying or contributing causes of death) in US adults. We note that the relation between outpatient antibiotic prescribing and the rates of septicemia hospitalization may be different from the relation between outpatient antibiotic prescribing and the rates of septicemia mortality. Indeed, case-fatality rates for hospitalizations with septicemia depend on the types of infection leading to septicemia, including their antibiotic resistance profiles [12, 13] , demographic factors, including presence of comorbidities [13, 20] , practices for antibiotic prescribing in the treatment of inpatients with septicemia [12] , etc. Moreover, major differences exit in coding practices for a septicemia diagnosis in hospitalized patients, with those differences further contributing to differences in case fatality rates for inpatients with septicemia in the hospitalization diagnosis. For example, a study from Kaiser Permanente Northern California suggested that inhospital fatality rates for their inpatients with hospitalization codes for septicemia/sepsis were significantly lower compared to the NIS data [21] . In this study, we use a multivariable regression framework to relate the rates of outpatient prescribing of fluoroquinolones, penicillins, cephalosporins and macrolides to the rates of septicemia mortality in different age groups of US adults, adjusting for additional effects. We hope that such ecological analyses can lead to further study of the contribution of different antibiotics to the rates of sepsis mortality, including the utility of a shift in prescribing from some antibiotics to certain others in the treatment of different syndromes for reducing the levels of sepsis mortality in the US.
Methods

Data
We extracted data on annual state-specific mortality with septicemia (ICD-10 codes A40-A41 representing either the underlying or a contributing cause of death) between 2013-2014 for different age groups of adults (18-49y, 50-64y, 65-74y, 75-84y, 85+y) from the US CDC Wonder database [22] . We note that for the majority of those deaths, septicemia is listed as a contributing, rather than the underlying cause of death on the death certificate [23] . Data on the annual state-specific per capita rates of outpatient prescribing for four classes of antibiotics: fluoroquinolones, penicillins, macrolides, and cephalosporins in 2013 and 2014 were obtain from the US CDC Antibiotic Patient Safety Atlas database [24] . Data on median household income for US states between 2013-2013 were extracted from [25] . Data on average monthly temperature for US states were obtained from [26] . Annual state-specific population estimates, including ones of African American populations in different age groups were extracted from [27] . Data on the percent of state residents who lived below the poverty level, and those who lacked health insurance were extracted form the US Census Bureau database [28] .
Regression model
For each age group of adults, (18-49y, 50-64y, 65-74y, 75-84y, 85+y), we applied multivariable linear regression to relate the average annual state-specific outpatient prescribing rates (per 1,000 state residents) for fluoroquinolones, penicillins, macrolides, and cephalosporins between 2013-2014 to the average annual statespecific rates of septicemia mortality per 100,000 individuals in a given age group between 2013-2014 (dependent variable). Besides the antibiotic prescribing rates, the other covariates were the state-specific median household income, percentages of state residents in a given age group who lived below the poverty level, those who were African American, those who lacked health insurance (in the non-elderly age groups, as health insurance, particularly Medicare coverage levels in the elderly are very high), as well as the state-specific average annual temperature. We note that septicemia mortality rates in African Americans are elevated [29] . We also note that temperature may influence bacterial growth rates and/or transmission mediated effects [30] , which in turn may affect both the prevalence of antibiotic resistance [30, 19] , and the acquisition/severity of bacterial infections. (ii) the 10 US HHS regions. Table 2 shows the estimates, for each age group of US adults, of the regression coefficients for the different covariates in the regression model (eq. 1). Those regression coefficients estimate the change in septicemia mortality rates (per 100,000 individuals in a given age group) when the corresponding covariate increases by 1. (-0.37,1) X X X Table 2 : Estimates of the regression coefficients for the different covariates in the inference model (eq. 1). Each coefficient estimates the change in septicemia mortality rates (per 100,000 individuals in a given age group) when the corresponding covariate increases by 1.
Results
Discussion
Rates of septicemia/sepsis hospitalization and associated mortality in the US have risen during the recent years [1, 2] . While outpatient antibiotic prescribing can contribute to progression to septicemia hospitalization (Introduction), and affect the resistance profiles for infections in hospitalized patients, which in turn affect their likelihood of survival [12, 13] , there is limited information on the strength of the relation between the levels of outpatient prescribing of different antibiotics and septicemia mortality rates in the US. In this study, we used a multivariable regression framework to relate the rates of outpatient prescribing of fluoroquinolones, penicillins, cephalosporins and macrolides to septicemia mortality rates in different groups of US adults. We have found that rates of penicillin prescribing are associated with septicemia mortality rates in older adults, which agrees with our earlier finding about the association between the rates of penicillin prescribing and the rates of septicemia hospitalization in older US adults [10] . We also note the high prevalence of resistance to penicillins in both the Gram-negative and Gram-positive bacteria (e.g.
[ [31] [32] [33] ). We have also found an association between the rates of cephalosporin prescribing and the rates of septicemia mortality in persons aged 18-49 years and 65-75 years, as well as the rates of fluoroquinolone prescribing and the rates of septicemia mortality in persons aged 18-49 years. We note that prevalence of cephalosporin resistance and the frequency of extended-spectrum beta-lactamase (ESBL) production, including in Gram-negative bacteria is growing [34] . We also note the high prevalence of fluoroquinolone resistance for some of the syndromes contributing to sepsis mortality, e.g. [35] . Additionally, we found that the share of African Americans in an age group is associated with septicemia mortality rate within that age group for persons aged over 65 years, and 18-49 years in the multivariable analysis, which agrees with the findings that rates of septicemia mortality and hospitalization in African Americans are elevated [29, 36] . We also found that the percent of state residents aged 65-74 years living below the poverty level is associated with septicemia mortality rate in that age group.
Our analyses have not found associations between the rates of fluroquinolone prescribing in older adults, as well as the rates of macrolide prescribing and the rates of septicemia mortality. If (like all models) this model is somewhat mis-specified, competition with antibiotics that are more likely to promote sepsis mortality could bias downward the strength of the association between the use of other antibiotics and the rates of sepsis mortality. Additionally, various sources of noise, such as the fact that we related antibiotic prescribing rates in the population overall to rates of septicemia mortality in different age groups, might have reduced the precision of our estimates. We note the high prevalence of resistance to fluoroquinolones for certain syndromes that contribute to sepsis mortality, like urinary tract infections (UTIs) in older adults [31] . Macrolide use could potentially contribute to the rates of sepsis mortality as macrolides are commonly prescribed for the treatment of certain syndromes that are major causes of sepsis, notably respiratory diseases, both chronic [37] and acute, including pneumonia [38] . Overall, the potential benefits of antibiotic stewardship for penicillins in older adults, cephalosporins and fluoroquinolones in younger adults, as well as cephalosporins in persons aged 65-74 years may be the most important findings of this paper, while options for antibiotic replacement require further investigation. We note that recently, US FDA recommended the restriction of fluoroquinolone use for certain conditions (such as uncomplicated UTIs) due to potential adverse effects [39] . Our results suggest that replacement of fluoroquinolones by penicillins and cephalosporins in treating older US adults could potentially lead to increases in septicemia mortality, with that issue needing further study.
Our study has some additional limitations. The antibiotic-sepsis incidence associations we find estimate causal effects only if the model is well-specified and all confounders are accounted for in the analysis. To adjust for potential effects of unmeasured and residual confounding, we included random effects for the ten US Health and Human
Services regions, which led to an improvement in the model fits. Further work involving more granular data is needed to ascertain the strength of the associations found in this paper. Data on outpatient antibiotic prescribing in the whole population were used in the regression model for which the outcomes were age-specific rates of septicemia hospitalization. We expect that this source of incompatibility should generally introduce noise into the regression model, reducing precision rather than creating spurious associations.
We believe that despite those limitations, our findings indicate a possible causal association between the use of penicillins and rates of sepsis mortality in older adults, as well as the use of cephalosporins and rates of sepsis mortality in persons aged 18-49 years and 65-74 years, and the use of fluoroquinolones and rates of sepsis mortality in persons aged 18-49 years. We hope that this population-level study would lead to further investigations of the relation between antibiotic prescribing practices and sepsis mortality in different contexts, including the potential effect of antibiotic replacement in the treatment of different syndromes on the rates of sepsis mortality.
